115279-57-7

Usage

Chemical Properties

light yellow crystalline

InChI:InChI=1/C10H12N2/c1-10(2,7-11)8-3-5-9(12)6-4-8/h3-6H,12H2,1-2H3

Upstream product

• 1195-98-8 2-methyl-2-phenylpropionitrile 
• 1962-08-9 4-(prop-1-en-2-yl)aniline 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 99-92-3 p-aminobenzophenone 
• 6625-74-7 N-pivaloylaniline 
• 101184-73-0 2-(4-bromophenyl)-2-methylpropanenitrile 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 

Downstream Products

• 36402-24-1 2-(4-amino-phenyl)-2-methyl-propionic acid 
• 145208-37-3 N-<4-(1-Cyano-1-methylethyl)phenyl>-5-methylisoxazole-4-carboxamide 
• 129488-62-6 N-[4-(1-Cyano-1-methylethyl)-phenyl]-4-methoxybenzamide 
• 1067192-53-3 2-(4-amino-3-chloro-phenyl)-2-methyl-propionitrile 
• 1067193-04-7 N-[4-(cyano-dimethyl-methyl)-phenyl]-4,5-dimethoxy-2-nitro-benzamide 
• 1067189-44-9 ADX₆₁₆₂₃ 
• 1067191-52-9 2-chloro-N-[4-(cyano-dimethyl-methyl)-phenyl]-4,5-dimethoxy-benzamide 
• 1067191-48-3 2-chloro-N-[4-(cyano-dimethyl-methyl)-phenyl]-3,4-dimethoxy-benzamide 
• 1220700-74-2 C₃₀H₂₅N₅O₂ 
• 1260167-62-1 2-methyl-2-(4-(8-methyl-2-oxo-3-(m-tolylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1260167-64-3 2-(4-(3-(3-fluorophenylsulfonyl)-8-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1260168-07-7 2-methyl-2-(4-(8-methyl-3-(2-methyl-5-nitrophenylsulfonyl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1260167-66-5 2-methyl-2-(4-(8-methyl-2-oxo-3-(quinolin-8-ylsulfonyl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile 
• 1260167-68-7 2-(4-(3-(4-acetylphenylsulfonyl)-8-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 

Relevant academic research and scientific papers

Metal-free site-selective C-H cyanoalkylation of 8-aminoquinoline and aniline-derived amides with azobisisobutyronitrile

Using K2S2O8, an efficient and metal-free site-selective C-H cyanoalkylation of 8-aminoquinoline and aniline-derived amides with AIBN (azobisisobutyronitrile) was developed. Without any catalyst, various substrates and functional groups were compatible to afford corresponding products in moderate to high yields. A mechanism study displayed that a radical-radical coupling process was involved via the N-centered radical generation and delocalization of aryl amides.

Preparation method of 2,2 - (2 - aminophenyl) 4 - methylpropionitrile compound synthesized from -2 - dimethyl - N N-phenyl-propionamide (by machine translation)

The invention relates to a preparation method of 2 - (4 - aminophenyl) -2 - methylpropionitrile compound. The method takes 2,2 - dimethyl - N N-phenyl-propionamide as an initial raw material, C-H activation reaction with azobisisobutyronitrile to obtain the intermediate product N - [4 - (cyano-dimethyl-methyl)-phenyl] -2, 2 -dimethyl-propionamide under the action of a catalyst such as transition metal ruthenium and nickel. The reaction total yield of the 2 - (4 - aminophenyl) -2 - methylpropionitrile product is higher than 70% . the reaction conditions are mild, the experiment operation process is simple, and a new preparation approach is provided for industrial production of the propionitrile aniline compound. (by machine translation)

Synthesis of Tertiary Benzylic Nitriles via Nickel-Catalyzed Markovnikov Hydrocyanation of α-Substituted Styrenes

The Markovnikov hydrocyanation of α-substituted styrenes enables the synthesis of tertiary benzylic nitriles under nickel catalysis. The Lewis-acid-free transformation features an unprecedented functional groups tolerance, including the-OH and-NH2 groups. A broad range of tertiary benzylic nitriles were obtained in good to excellent yields. In addition, an asymmetric version of this reaction was preliminarily investigated.

Five-membered urea link and coumarin derivative or its pharmaceutically acceptable salts and use

The invention relates to a small molecule medicament based on PI3K (Phosphatidyl Inositol 3-kinase)/mTOR (Mammalian Target of Rapamycin) double targets, belongs to the technical field of chemical medicines, and in particular relates to a five-membered urea ring-coumarin derivative or a pharmaceutical salt and an application thereof. A compound claimed by the invention has a structure shown as formula I described in the specification, and pharmacological experiments show that the compound has excellent inhibitory activity in a plurality of tumor cell strains.

Imidazole derivatives, its pharmaceutical composition and use thereof

Imidazolone compounds, pharmaceutically acceptable salts, solvates, polymorphs or prodrugs thereof are disclosed. Pharmaceutical compositions comprising above substances and uses for preventing and treating protein kinases related diseases, such as cancers, metabolic diseases, cardiovascular diseases and the like, are also disclosed.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

JAK PI3K/mTOR combination therapy

Provided herein is a combination therapy comprising a JAK kinase inhibitor and a dual PI3K/mTOR inhibitor, as well as methods of treating various cancers through the use of such a combination therapy.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation

A series of quinoline derivatives featuring the novelty of introducing intra-molecular hydrogen bonding scaffold (iMHBS) were designed, synthesized and biologically evaluated for their mTOR inhibitory activity, as well as anti-proliferative efficacies aga

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.